세계의 진통제 시장 규모는 2023년에 305억 9,900만 달러에 달했습니다. 이 시장은 2024-2030년의 예측 기간 중 CAGR 6.84%로 성장하며, 2030년에는 453억 8,900만 달러에 달할 것으로 예측됩니다. 정형외과 질환, 암 및 기타 만성질환의 유병률 증가는 효과적인 통증 관리 솔루션을 찾는 환자들 수요를 증가시켜 진통제에 대한 수요를 크게 증가시킬 것입니다. 특히 고령층에서 관절염과 골다공증과 같은 질환의 발병률이 높아지면서 경증 및 중등도 통증에 대한 진통제의 필요성이 증가하고 있습니다. 또한 암 환자들은 질병이나 치료의 부작용으로 인한 통증을 관리하기 위해 진통제를 자주 필요로 합니다. 이러한 수요 증가에 힘입어 전 세계에서 진통제 신제품이 잇따라 승인 및 출시되면서 의료진과 환자 모두에게 선택의 폭이 넓어지고 있습니다. 따라서 2024-2030년의 예측 기간 중 이러한 요인들이 종합적으로 진통제 시장을 촉진할 것으로 예상됩니다.
가장 흔한 관절염인 골관절염은 2050년까지 약 10억 명이 발병할 것으로 예상됩니다.
2050년까지 10억 명에 가까운 사람들이 골관절염을 앓게 될 것으로 예측됩니다. 현재 30세 이상 인구의 15%가 골관절염을 경험하고 있습니다. 2050년까지 무릎과 손의 골관절염이 가장 많이 발생하는 부위는 무릎과 손이며, 2050년까지 무릎 골관절염은 75%, 손 골관절염은 50% 증가할 것으로 예상되고 있습니다. 또한 호주 통계청이 최근 발표한 최신 정보(2023년)에 따르면 2022년에는 370만 명 미만(14.5%)이 관절염을 앓고 있으며, 45-54세 연령층에서는 그 비율이 0-44세보다 약 7배(2.5% 대비 16.2%) 높으며, 45-54세와 55-64세 연령대에서는 유병률은 거의 두 배로 증가했으며(30.5% 대비 16.2%), 75세 이상 노인은 다른 연령대보다 관절염에 걸릴 확률이 높아 2022년에는 2명 중 1명(48.9%)이 관절염을 앓고 있을 것으로 예측되었습니다. 골관절염은 관절 연골과 그 아래 뼈의 퇴행성 변화로 지속적인 통증, 뻣뻣함, 운동 능력 저하를 유발하는 질환으로, 전 세계에서 수백만 명이 앓고 있으며, 특히 고령화 사회로 접어들면서 더욱 심각해지고 있습니다. 골관절염 진단을 받는 인구가 증가함에 따라 효과적인 진통제에 대한 수요도 증가하고 있습니다.
세계의 진통제 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 용도별, 약제 유형별, 유통 채널별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
Analgesics Market by Product Type (Opioid and Non-Opioid), Application (Musculoskeletal, Surgical & Trauma, Cancer, and Others), Drug Type (Prescription and Over-The-Counter (OTC)) Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases, rising demand for analgesics for the treatment of mild to moderate pain, and increased product approval across the globe.
The global analgesics market was valued at USD 30,599 million in 2023, growing at a CAGR of 6.84% during the forecast period from 2024 to 2030 to reach USD 45,389 million by 2030. The increasing prevalence of orthopedic conditions, cancer, and other chronic diseases significantly boosts the demand for analgesics as patients seek effective pain management solutions. With conditions like arthritis and osteoporosis becoming more common, particularly among aging populations, the need for reliable pain relief for mild to moderate pain intensifies. Additionally, cancer patients frequently require analgesics to manage pain associated with their condition and treatment side effects. This rising demand is further propelled by the consistent approval and introduction of new analgesic products globally, expanding the range of available options for both healthcare providers and patients. Thus, these factors collectively boost the analgesics market, during the forecast period from 2024 to 2030.
Analgesics Market Dynamics:
According to a recent study published under the Global Burden of Disease (2023), nearly 1
billion people were projected to be living with osteoarthritis, the most common form of
Arthritis, by 2050. Currently, 15% of individuals aged 30 and older experience osteoarthritis. The most common sites for osteoarthritis are the knees and hands. By 2050, cases of osteoarthritis of the knee are expected to increase by 75%, while cases of Osteoarthritis of the hand are anticipated to rise by 50%. Additionally, as per the recent update provided by the Australian Bureau of Statistics (2023), in 2022, under 3.7 million (14.5%) people had arthritis. For individuals aged 45-54 years, the proportion is almost seven times higher than for those aged 0-44 years (16.2% compared to 2.5%). The prevalence almost doubled between the ages of 45-54 years and 55-64 years (16.2% compared to 30.5%). Older adults aged 75 years and over were more likely than any other age group to have arthritis, with almost one in two (48.9%) having the condition in 2022. Osteoarthritis, characterized by the degeneration of joint cartilage and underlying bone, leads to persistent pain, stiffness, and reduced mobility, affecting millions globally, especially among the aging population. As the number of individuals diagnosed with osteoarthritis rises, so does the demand for effective pain analgesics increases. As arthritis commonly results in chronic pain and inflammation, affected individuals often seek immediate and accessible relief. Medications such as tramadol, hydrocodone, and oxycodone are widely used to manage Arthritis symptoms thereby boosting the overall market of analgesics.
Additionally, the rising demand for analgesics for the treatment of mild to moderate pain such as in the case of toothache, headache, pain due to strenuous physical activity, period pain, and others is another factor accelerating the growth of the analgesics market. For instance, in October 2023, Hyloris Pharmaceuticals, a pharmaceutical company headquartered in Belgium, announced the approval of a potent non-opioid painkiller in the United States. Consequently, the continuous introduction of innovative pain management analgesics, coupled with the widespread and varied applications of analgesics, fuels the robust growth of the analgesics market.
However, growing concern over opioid abuse and stringent regulatory policies may act as a restraint in the market growth for analgesics during the forecasted period.
Analgesics Market Segment Analysis:
Analgesics Market by Product Type (Opioid and Non-Opioid), Application (Musculoskeletal, Surgical & Trauma, Cancer, and Others), Drug Type (Prescription and Over-The-Counter (OTC)), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the analgesics market, the non-opioid category is estimated to have a significant revenue share in the analgesics market in 2023. Non-opioid analgesics are suitable and effective for a wide variety of pain and inflammatory conditions including musculoskeletal pain due to rheumatic disorders. They seem to have fewer side effects associated with them than opioid analgesics. The commonly used non-opioid analgesics are acetaminophen (paracetamol), antidepressants such as duloxetine and amitriptyline, aspirin and other non-steroidal anti-inflammatory agents (NSAIDS), and topical agents such as lidocaine and capsaicin among others. Acetaminophen is indicated for mild to moderate pain such as in case of headache, period pain, backaches, and others. It is regarded as the first line of therapy for pain and fever, particularly in the case of viral infections. Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain, have antipyretic properties, prevent blood clots, and can reduce inflammation by blocking enzymes such as prostaglandins that are responsible for causing pain and inflammation in the body.
The increasing number of research studies related to the evaluation of the role of non-opioid analgesics is further going to enhance the demand for non-opioid analgesics. For instance, in November 2021, Northwestern University in collaboration with the National Institutes of Health (NIH) started a clinical study that aims to determine whether the treatment with Carbidopa/Levodopa and Naproxen in females with acute pain after a bunionectomy or toe fusion (24hrs, 48hrs and 5 days) will reduce pain when compared with females receiving Placebo and Naproxen.
Therefore, owing to the above-mentioned factors, the non-opioids category is expected to generate considerable revenue thereby pushing the overall growth of the global analgesics market during the forecast period.
North America is expected to dominate the overall analgesics market:
North America is expected to account for the highest proportion of the Analgesics market in 2023, out of all regions. This can be due to factors including the prevalence of chronic and infectious diseases such as orthopedic, cardiovascular, tuberculosis, and cancer among others, the increasing old age population, and the presence of key companies involved in the development of analgesics, and others.
According to recent data from the GLOBOCAN, in 2022, North America saw an estimated 2.67 million new cases of cancer, with forecasts indicating a rise to 3.83 million by 2045. As per the same source, in Canada, the number of new cancer cases was around 292,000 in 2022, projected to reach 449,000 by 2045. Meanwhile, in Mexico, there were approximately 207,000 new cases of cancer in 2022, expected to increase to 360,000 by 2045. Cancer patients often experience severe pain due to the disease itself, treatment procedures, and associated complications. As the incidence of cancer rises, the demand for effective pain relief solutions intensifies, encompassing both prescription opioids and non-opioid analgesics increases thereby boosting the overall market of analgesics.
As per the recent data provided by the Centre for Disease Control and Prevention (CDC) (2023), from 2019 to 2021, statistics revealed that about 21.2% of adults in the United States, totaling approximately 53.2 million individuals, were diagnosed with arthritis by a healthcare professional. Among these, women experienced a higher prevalence, with 20.9% affected, compared to 16.3% of men. Moreover, veterans exhibited a higher prevalence of arthritis at 24.2%, surpassing the 18.5% prevalence rate among non-veterans. Additionally, the likelihood of being diagnosed with arthritis increases with age. These conditions often lead to severe joint pain, deformities, and loss of function, necessitating analgesics such as Acetaminophen, Ibuprofen, Naproxen, and others thereby boosting the future market in North America.
Along with the presence of a large patient pool in the country, the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the analgesics market in the United States during the forecast period. For example, in October 2021, Esteve Pharmaceuticals received the US Food and Drug Administration (FDA) clearance for SEGLENTIS(R) (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Therefore, the above-mentioned factors are expected to bolster the growth of the analgesics market in the United States during the forecast period.
Analgesics Market Key Players:
Some of the key market players operating in the Analgesics market include Novartis AG, Pfizer Inc., Bayer AG, AbbVie Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi, Assertio Holdings, Inc., Janssen Pharmaceuticals, Inc., GSK plc., Perrigo Company plc., Mallinckrodt, Purdue Pharma L.P., Abbott, Reckitt Benckiser Group PLC., Fresenius Kabi USA, Eliy and Lilly Company, Hikma Pharmaceuticals PLC, Heron Therapeutics, Inc., and others.
Recent Developmental Activities in the Analgesics Market:
Key Takeaways From the Analgesics Market Report Study:
Target Audience who can be benefited from this analgesics Market Report Study:
Frequently Asked Questions for the Analgesics Market:
Analgesics, commonly known as painkillers, are medications designed to relieve pain without causing the loss of consciousness. They are used to alleviate various types of pain, ranging from mild to severe, and can be administered for acute conditions, such as injuries or surgeries, as well as chronic conditions, like arthritis or cancer. Analgesics work by acting on the nervous system to reduce or block the sensation of pain.
The global analgesics market was valued at USD 30,599 million in 2023, growing at a CAGR of 6.84% during the forecast period from 2024 to 2030 to reach USD 45,389 million by 2030.
The increasing prevalence of orthopedic conditions, cancer, and other chronic diseases significantly boosts the demand for analgesics as patients seek effective pain management solutions. With conditions like arthritis and osteoporosis becoming more common, particularly among aging populations, the need for reliable pain relief for mild to moderate pain intensifies. Additionally, cancer patients frequently require analgesics to manage pain associated with their condition and treatment side effects. This rising demand is further propelled by the consistent approval and introduction of new analgesic products globally, expanding the range of available options for both healthcare providers and patients. Thus, these factors collectively boost the analgesics market, during the forecast period from 2024 to 2030.
Some of the key market players operating in the Analgesics are Novartis AG, Pfizer Inc., Bayer AG, AbbVie Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi, Assertio Holdings, Inc., Janssen Pharmaceuticals, Inc., GSK plc., Perrigo Company plc., Mallinckrodt, Purdue Pharma L.P., Abbott, Reckitt Benckiser Group PLC., Fresenius Kabi USA, Eli and Lilly Company, Hikma Pharmaceuticals PLC, Heron Therapeutics, Inc., and others.
North America is expected to account for the highest proportion of the Analgesics market in 2023, out of all regions. This can be due to factors including the prevalence of chronic and infectious diseases such as orthopedic, cardiovascular, tuberculosis, and cancer among others, the increasing old age population, and the presence of key companies involved in the development of analgesics, and others.